Jeffrey Scott C, Nguyen Minh T, Moser Ruth F, Meyer Damon L, Miyamoto Jamie B, Senter Peter D
Seattle Genetics Inc., 21823 30th Drive S.E., Bothell, WA 98021, USA.
Bioorg Med Chem Lett. 2007 Apr 15;17(8):2278-80. doi: 10.1016/j.bmcl.2007.01.071. Epub 2007 Jan 27.
The minor groove binder beta-glucuronide drug-linker 3 was constructed from amino CBI 1 and determined to be a substrate for Escherichia coli beta-glucuronidase (EC 3.2.1.31), resulting in facile drug release. Compound 3 was conjugated to mAbs cAC10 (anti-CD30) and h1F6 (anti-CD70) to give antibody-drug conjugates (ADCs) with potencies comparable to that of free drug 1. The ADCs were largely monomeric at intermediate loading levels (4-5drug/mAb), in contrast to highly aggregated p-aminobenzylcarbamate dipeptide-based ADCs of 1 previously reported. Significant levels of immunologic specificity were observed with cAC10-3 by comparing antigen positive versus negative cell lines and binding versus non-binding control ADCs. The water soluble beta-glucuronide linker is stable in plasma and effectively delivers drugs to target cells leading to potent cytotoxic activities.
小沟结合剂β-葡萄糖醛酸苷药物连接体3由氨基CBI 1构建而成,并被确定为大肠杆菌β-葡萄糖醛酸酶(EC 3.2.1.31)的底物,从而实现药物的轻松释放。化合物3与单克隆抗体cAC10(抗CD30)和h1F6(抗CD70)偶联,得到效价与游离药物1相当的抗体-药物偶联物(ADC)。与先前报道的基于对氨基苄基氨基甲酸酯二肽的高度聚集的ADC相比,这些ADC在中等负载水平(4-5个药物/单克隆抗体)下主要为单体形式。通过比较抗原阳性与阴性细胞系以及结合与非结合对照ADC,观察到cAC10-3具有显著水平的免疫特异性。水溶性β-葡萄糖醛酸苷连接体在血浆中稳定,并能有效地将药物递送至靶细胞,从而产生强大的细胞毒活性。